Maybe more importantly, this work clearly showed that combining oxaliplatin with an anti-PD-L1 monoclonal antibody led to an increased tumor infiltration of CD8+ T-cells, especially when the anti-PD-L1 molecule was injected before oxaliplatin. This evidence concerns the gene CD8A and neoplasm.